Vanda Pharmaceuticals Inc. (VNDA) company profile
Close on Nov 18, 2026Market cap $226.76MP/E –Yield –
About Vanda Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders and other medical conditions. Its commercial product lineup includes Fanapt for schizophrenia and bipolar I disorder, Hetlioz for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome sleep disturbances, Ponvory for relapsing forms of multiple sclerosis, and Nereus for motion-induced vomiting. The company operates in a product segment and distributes its medications primarily to wholesale drug distributors and specialty pharmacies.
The company is based in Washington, D.C., where it maintains its principal executive offices. Its commercial operations center on the United States, alongside product distribution in select international markets including Canada, Israel, and European nations such as the United Kingdom. Its operations encompass four commercial-stage prescription medicines along with multiple drug candidates undergoing clinical development.
Summary of the business section of Vanda Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vanda Pharmaceuticals Inc.
- Founded
- 2002
- Headquarters
- Washington, DC
- Address
- 2200 Pennsylvania Ave Nw, Suite 300e 20037
- Phone
- (202) 734-3400
- Website
- www.vandapharma.com
- Employees
- 533, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Washington, District of Columbia
Stock & identifiers
- Ticker
- VNDA
- Exchange
- Nasdaq
- IPO date
- Apr 13, 2006
- Shares outstanding
- 60M, Oct 22, 2026
- Public float
- $268.70M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1347178
- CUSIP
- 921659108
- ISIN
- US9216591084
- FIGI
- BBG000HT5MG6
- Share class FIGI
- BBG001SP95N5
- LEI
- 529900AY8VOOQBKJ0O70
- EIN
- 03-0491827
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mihael Hristos Polymeropoulos | President and CEO, Director | 2,704,496 |
| Daniel Patrick McGuire | SVP, GC and Secretary | 109,982 |
| Christos Vasilios Mihael Polymeropoulos | Senior VP, Medical Director | 129,791 |
| Scott Laverne Howell | VP and Chief People Officer | 109,620 |
| Joakim Wijkstrom | SVP, Chief Marketing Officer | 333,469 |
| Timothy Williams | SVP & General Counsel | 377,450 |
| Gunther Birznieks | SVP, Business Development | 494,197 |
| Kevin Patrick Moran | SVP, CFO & Treasurer | 412,015 |
| Charles Cliff Duncan | Director | 108,701 |
| Richard W. Dugan | Director | 219,054 |
| Phaedra Chrousos | Director | 164,950 |
| Anne Sempowski Ward | Director | 160,667 |
| Stephen Ray Mitchell | Director | 112,846 |
| Tage Honore | Director | 135,069 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.85M | $7.63M | $1.44M | $67 | $120 |
| FY2024 | $3.90M | $4.34M | $1.35M | $36 | $91 |
| FY2023 | $3.72M | $1.78M | $1.36M | $32 | $92 |
| FY2022 | $4.27M | $859.61K | $1.51M | $56 | $89 |
| FY2021 | $6.19M | $5.60M | $1.96M | $119 | $99 |
| FY2020 | $2.91M | $2.06M | $1.15M | $80 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Mihael H. Polymeropoulos, M.D. President, Chief Executive Officer and Chairman of the Board | $965.66K | $2.01M | $834.33K | $44.49K | $3.85M | -1% |
| Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | $559.94K | $557.50K | $272.13K | $50.10K | $1.44M | -1% |
| Gunther Birznieks Senior Vice President, Business Development | $559.94K | $557.50K | $272.13K | $25.91K | $1.42M | -1% |
| Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | $579.60K | $557.50K | $281.69K | $38.74K | $1.46M | +37% |
| Timothy Williams Senior Vice President, General Counsel and Secretary | $559.94K | $557.50K | $272.13K | $55.41K | $1.44M | -1% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 13, 2006
- Offer price
- $10.00
- Securities offered
- 5,750,000
- Gross proceeds
- $57.50M
- Exchange
- Nasdaq
- First trading day
- Apr 12, 2006
- First-day close
- $9.68-3.2%
- Lock-up ends (est.)
- Oct 9, 2006
“Our common stock has been approved for quotation on the Nasdaq National Market under the symbol “VNDA.” Per share Total Initial public offering price $ 10.00 $ 57,500,000 Underwriting discounts and commissions $ 0.70 $ 4,025,000 Proceeds to us, before expenses $ 9.30 $ 53,475,000 We have granted the underwriters an option for a period of 30 days to purchase up to 862,500 additional shares of common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We had 533 full-time employees as of December 31, 2025, compared with 368 employees as of December 31, 2024.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 17, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 7, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 25, 2008 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 13, 2006 | IPO | Initial public offering priced (424B4 prospectus) |
See a number that looks wrong?